Yvonne Perrie
University of Strathclyde, UK
My current position is Professor in Drug Delivery within the Strathclyde Institute of Pharmacy and Biomedical 新月直播app下载s, University of Strathclyde, Glasgow, Scotland. In 1998 I gained my PhD from the University of London investigating the role of liposomes for DNA vaccines and drug delivery. I then worked within a newly established Drug Delivery Company (Lipoxen Technologies Ltd) for two years, developing their liposome drug delivery platform technology before moving into Academia to set up my own research group. I joined Aston University in 2000 and was appointed Professor in Drug Delivery in 2007. In 2016, I moved to the University of Strathclyde as Professor in Drug Delivery as part of the Global Talent Appointment Programme where I continue to develop and advance my research strategies.
My research is multi-disciplinary and focuses on developing drug delivery systems to facilitate the delivery of drugs and vaccines, thus providing practical solutions for current healthcare problems. I am an internationally recognised expert in the field of liposomes and particulate drug delivery research. My laboratory is fully equipped to manufacture and analyze a wide range of nanoparticles, including a suite of microfluidic systems that will provide the underpinning support for this project. I maintain a steady funding stream to support my research team through various sources, including Government Research Councils, European Framework Funding, Industrial Partners, and Charities.
My research and academic leadership has been recognised via a range of fellowships and awards including the Royal Pharmaceutical Society Harrison Memorial Medal (2019), 50th Anniversary Chair in Drug Delivery (2016), membership of the Controlled Release Society College of Fellows (2015), Fellow of the Royal Pharmaceutical Society (2014), Fellow of the Royal Society of Biology (2012), Eminent Fellow of the Academy of Pharmaceutical 新月直播app下载s (2012), the Royal Pharmaceutical Society Pharmaceutical Scientist of the Year (2012), the British 新月直播app下载 Festival Collaboration in Formulation Award (2011) and the Royal Pharmaceutical Society 新月直播app下载 Conference Medal (2007).
Clare Hoskins, Associate Editor
University of Strathclyde, UK
Clare Hoskins is a Professor of Nanomedicine within the Department of Pure and Applied Chemistry, University of Strathclyde. She gained her undergraduate degree in Applied Chemistry and subsequent PhD in Pharmaceutics, from Robert Gordon University, Aberdeen. Following this she carried out a postdoc at the University of Dundee, before starting her independent academic career at the School of Pharmacy, Keele University. In 2019 she moved to the University of Strathclyde as part of their Global Talent Appointment Programme.
Clare is a Fellow of the 新月直播app下载 and the Chair of the Chemical Nanosciences and Nanotechnology Network. She is also a committee member of the UK & Ireland Controlled Release Society. Her research focusses on the development of various nanotechnology platforms for drug delivery and theranostics, with a special focus on cancer nanomedicine. Clare’s leadership and research have been recognised through various awards including Strathclyde Medals, Strathclyde Women in Leadership awards and the Academy of Pharmaceutical 新月直播app下载s ‘Emerging Scientist’ sponsored by Pfizer. She is a keen advocate of equality, diversity and inclusion within the chemical and pharmaceutical sciences, and has contributed to various teams challenging bias within our discipline, as well as being a panel reviewer for Athena Swan.
Xiaoxuan Liu, Associate Editor
China Pharmaceutical University, China
Xiaoxuan Liu is a Professor at the Center of Advanced Pharmaceuticals and Biomaterials in China Pharmaceutical University. She received her Ph.D degree in Organic Chemistry in 2010 from Wuhan University and Aix-Marseille University, and thereafter got her postdoctoral training at Centre Interdisciplinaire de Nanoscience de Marseille (CINaM) and Center of Research in Cancerology of Marseille (CRCM) in France. Her research interest focuses on the development of novel dendrimer based nanosystems via modular self-assembling process for on-demand delivery of drugs and nucleic acid therapeutics in precision medicine. She was the recipient of the National Youth Talent of China (2016), and the “Distinguished Professor’’ of Jiangsu Province (2015).
Heidi Mansour, Associate Editor
Florida International University, USA
Dr. Mansour is currently a Professor and Program Leader of Drug Discovery and Delivery at the Florida International University (FIU) Center for Translational 新月直播app下载 located in Port Saint Lucie, Florida on the beautiful Treasure Coast. Professor Mansour is a tenured Full Professor in the Robert Stempel College of Public Health and Social Work in the Department of Environmental Health 新月直播app下载s and also a faculty member in the Herbert Wertheim College of Medicine in the Department of Cellular Biology and Pharmacology. She is a Senior Member of the National Academy of Inventors (NAI) and a Fellow of the American Institute of Medical and Biological Engineering (AIMBE).
Her innovative research program has produced faculty members employed at major research universities in the United States and the Republic of South Korea. In addition, her research program has produced Senior Scientists employed at major pharmaceutical companies in the United States. She has co-edited 2 books and has published 16 book chapters and 116 journal publications (Please see for details). Dr. Mansour is an inventor with 10 patents and has exclusive licenses.
Assaf Zinger, Associate Editor
Technion - Israel Institute of Technology, Israel, & Houston Methodist Academic Institute, USA
Dr. Assaf Zinger is a leading researcher and educator specializing in nanomedicine and engineering. He is currently an Assistant Professor at the Technion-Israel Institute of Technology and an Adjunct Assistant Professor at the Houston Methodist Academic Institute in Texas, USA. Dr. Zinger's research focuses on biomimetic nanoparticles, covering various fields from biochemical engineering, where he designs and tests these nanoparticles, to biomedical engineering, where he assesses their effectiveness against conditions like neurodegenerative diseases, brain injuries, and cancers.
Aside from his research, Dr. Zinger co-founded the "Tzameret Program," connecting Technion students with high school students to promote research and academic studies. He also contributed to the undergraduate excellence program "Lavie" in the chemical engineering department. His significant contributions have earned him over 15 national and international awards and honors, including the prestigious Alon Scholarship and the Umbrella Award in Life 新月直播app下载 and Engineering. He is a member of the Global Young Academy and an ERC starting grant recipient. You can learn more about his lab's work
Arvind Kumar Bansal, Editorial Board Member
National Institute of Pharmaceutical Education and Research (NIPER), India
Dr Arvind Kumar Bansal is currently Dean and Professor at the Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER) - SAS Nagar, Punjab, India. His areas of research include pharmaceutical material characterization, improvement of aqueous solubility using solid - state modification techniques like amorphous form, nanocrystals and co crystals, compaction physics and phase behaviour during lyophilisation. His research group works with the mission statement - ‘developing science based industrially viable pharmaceutical technologies’ and works closely with pharmaceutical industry to create opportunities for commercial exploitation of the products. Before joining NIPER, Prof Bansal worked as Senior Scientist and Group Leader in JK Pharmaceuticals and Ranbaxy Research Laboratories, for 8 years. He earned his M Pharm (Pharmaceutics) (1988) and Ph.D. (1993) from University of Delhi, India. Dr Bansal was conferred prestigious Fellow of American Association of Pharmaceutical 新月直播app下载s in 2016. He is the first Indian, working in India, to be awarded AAPS Fellow status.
